GIP-(3–42) does not antagonize insulinotropic effects of GIP at physiological concentrations
Authors:
- Carolyn F. DeaconCDCarolyn F. Deacon
- Astrid PlamboeckAPAstrid Plamboeck
- Mette M. RosenkildeMRMette M. Rosenkilde
- Jocelyn de HeerJHJocelyn de Heer
- Jens J. HolstJHJens J. Holst
- 1 September 2006
- journal article
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 291 (3) , E468-E475
Abstract
Glucose-dependent insulinotropic polypeptide [GIP-(1–42)] is degraded by dipeptidyl peptidase IV (DPP IV), forming GIP-(3–42). In mice, high concentrations of synthetic GIP-(3–42) may function as a GIP receptor antagonist, but it is unclear whether this occurs at physiological concentrations. In COS-7 cells transiently transfected with the human GIP receptor, GIP-(1–42) and -(3–42) bind with affinities (IC50) of 5.2 and 22 nM, respectively. GIP-(1–42) was a potent agonist, stimulating cAMP accumulation (EC50, 13.5 pM); GIP-(3–42) alone had no effect. When incubated together with native GIP, GIP-(3–42) behaved as a weak antagonist (IC50, 92 and 731 nM for inhibition of cAMP accumulation elicited by 10 pM and 1 nM native GIP, respectively). In the isolated perfused rat pancreas, GIP-(3–42) alone had no effect on insulin output and only reduced the response to GIP (1 nM) when coinfused in >50-fold molar excess (IC50, 138 nM). The ability of GIP-(3–42) to affect the antihyperglycemic or insulinotropic actions of GIP-(1–42) was examined in chloralose-anesthetized pigs given intravenous glucose. Endogenous DPP IV activity was inhibited to reduce degradation of the infused GIP-(1–42), which was infused alone and together with GIP-(3–42), at rates sufficient to mimic postprandial concentrations of each peptide. Glucose, insulin, and glucagon responses were identical irrespective of whether GIP-(1–42) was infused alone or together with GIP-(3–42). We conclude that, although GIP-(3–42) can weakly antagonize cAMP accumulation and insulin output in vitro, it does not behave as a physiological antagonist in vivo.Keywords
This publication has 38 references indexed in Scilit:
- [Ser2]- and [Ser(P)2]Incretin AnalogsJournal of Biological Chemistry, 2004
- Valine Pyrrolidide Preserves Intact Glucose‐Dependent Insulinotropic Peptide and Improves Abnormal Glucose Tolerance in Minipigs With Reduced β‐Cell MassJournal of Diabetes Research, 2003
- Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivoJournal of Endocrinology, 2002
- Characterization of the Carboxyl-terminal Domain of the Rat Glucose-dependent Insulinotropic Polypeptide (GIP) ReceptorJournal of Biological Chemistry, 1999
- The hepatic vagal nerve is receptive to incretin hormone glucagon-like peptide-l, but not to glucose-dependent insulinotropic polypeptide, in the portal veinJournal of the Autonomic Nervous System, 1996
- Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: ligand binding and intracellular signaling propertiesEndocrinology, 1995
- Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IVEndocrinology, 1995
- Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivoThe Journal of Clinical Endocrinology & Metabolism, 1995
- Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine.Journal of Clinical Investigation, 1991
- Actions of GIPPeptides, 1981